Search results
Dame Emma Natasha Walmsley DBE (born June 1969) is the chief executive officer (CEO) of GlaxoSmithKline. She succeeded Sir Andrew Witty, who retired in March 2017. Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. She grew up in Barrow-in-Furness, Cumbria, England.
Dame Emma Walmsley | Chief Executive Officer. Emma joined the Board as CEO Designate on 1 January 2017 and became CEO on 1 April 2017. She has been a member of the GSK Leadership Team since 2011, as the President and then CEO of GSK Consumer Healthcare.
May 21, 2024 · When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive officer of GSK Plc found her remedy in a product almost 60 years in the making.
View Emma Walmsley’s profile on LinkedIn, a professional community of 1 billion members. Proud to be leading GSK as we unite science, technology and talent to get ahead of… · Experience: GSK...
- GSK
Emma Walmsley. CEO, GSK. Photo by Luke MacGregor/Bloomberg. About Emma Walmsley. Walmsley became CEO of GlaxoSmithKline in April of 2017, making her the first woman to run a major pharmaceutical...
May 31, 2023 · On this week’s episode of Fortune‘s Leadership Next podcast, co-hosts Alan Murray and Michal Lev-Ram talk with GSK CEO Emma Walmsley about the future of A.I. in the pharmaceutical industry, the...
Early in 2023, British pharma giant GSK launched the world’s first RSV adult vaccine, Arexvy, for those aged 60 years and older. Walmsley, the only woman CEO of a major pharma company, told ...
Sep 20, 2016 · Emma Walmsley, the incoming GlaxoSmithKline chief executive, is a brands expert with more than two decades of experience in fast-moving consumer and luxury goods.
GSK today announces that Emma Walmsley, currently Chief Executive Officer (CEO) of GSK’s Consumer Healthcare division, is appointed GSK CEO Designate and will succeed Andrew Witty as GSK CEO, when he retires on 31 March 2017.
Jun 23, 2021 · GSK chief executive Emma Walmsley has pushed back against concerns over her leadership, saying she is a “change agent” committed to transforming the UK drugmaker after the spin-off of its...
